Key result
Personalizing athlete antithrombotics requires weighing individual bleeding and sport-specific trauma risks for competition.
Why the study?
Antithrombotic therapy in athletes requires tailoring based on individual bleeding and thrombotic risks and the intrinsic risk of sports activities when determining sports eligibility.
Personalized assessment of bleeding and thrombotic risks, considering the specific sport and concomitant NSAID use, is essential when prescribing antithrombotic therapy to competitive athletes.
Supports individualized bleeding and sport-risk assessment for athletes on antithrombotics; leaves open prospective trials to define eligibility criteria.
Antiplatelet and anticoagulation therapy are commonly used in the general population and sometimes in athletes experiencing cardiovascular disorders. In these cases, the treatment has to be tailored according to the individual bleeding and thrombotic risk profile, also considering the intrinsic risk of sports activities when advising athletes for eligibility for competitive sports. In athletes, it is necessary to pre-assess the individual bleeding risk, considering not only the personal bleeding risk (usually low in athletes) but also the type of sport the athlete would like to practice, with careful consideration in sports where traumatic collisions are highly likely. Additionally, non-steroidal anti-inflammatory drugs are commonly used among athletes, and antiplatelet therapy may further increase the bleeding risk. Therefore, in selected competitive athletes, the default approach for antithrombotic therapy could be personalized. This review discusses the clinical management challenges of competitive athletes under antithrombotic or antiplatelet therapy, focusing on the intrinsic risks of sports practice and the indications for sports eligibility and disqualification.
No takes yet. Share an insight, caveat, or question.
D’Ascenzi et al. (2025) conducted a review in Cardiovascular disorders requiring antithrombotic therapy in athletes. Antiplatelet and anticoagulation therapy was evaluated. Personalized antithrombotic therapy in athletes requires careful assessment of individual bleeding risks and the intrinsic traumatic risks of specific sports to determine eligibility for competition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: